{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:30:50Z","timestamp":1794544250513,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["Biogen POL-SMG-17-11166"],"award-info":[{"award-number":["Biogen POL-SMG-17-11166"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Spinal muscular atrophy (SMA) is an autosomal recessive disorder caused by a biallelic mutation in the <jats:italic>SMN1<\/jats:italic> gene, resulting in progressive muscle weakness and atrophy. Nusinersen is the first disease-modifying drug for all SMA types. We report on effectiveness and safety data from 120 adults and older children with SMA types 1c-3 treated with nusinersen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients were evaluated with the Hammersmith Functional Motor Scale Expanded (HFMSE; n\u2009=\u200973) or the Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND; n\u2009=\u200947). Additionally, the Revised Upper Limb Module (RULM) and 6-minute walk test (6MWT) were used in a subset of patients. Patients were followed for up to 30 months of nusinersen treatment (mean, SD; 23, 14 months). Subjective treatment outcomes were evaluated with the Patients Global Impression\u2013Improvement (PGI-I) scale used in all patients or caregivers at each follow-up visit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>An increase in the mean HFMSE score was noted at month 14 (T14) (3.9 points, p\u2009&lt;\u20090.001) and month 30 (T30) (5.1 points, p\u2009&lt;\u20090.001). The mean RULM score increased by 0.79 points at T14 (p\u2009=\u20090.001) and 1.96 points (p\u2009&lt;\u20090.001) at month 30 (T30). The mean CHOP-INTEND increased by 3.6 points at T14 (p\u2009&lt;\u20090.001) and 5.6 points at month 26 (p\u2009&lt;\u20090.001). The mean 6MWT improved by 16.6\u00a0m at T14 and 27\u00a0m at T30 vs. baseline. A clinically meaningful improvement in HFMSE (\u2265\u20093 points) was seen in 62% of patients at T14, and in 71% at T30; in CHOP INTEND (\u2265\u20094 points), in 58% of patients at T14 and in 80% at T30; in RULM (\u2265\u20092 points), in 26.6% of patients at T14 and in 43.5% at T30; and in 6MWT (\u2265\u200930-meter increase), in 26% of patients at T14 and in 50% at T30. Improved PGI-I scores were reported for 75% of patients at T14 and 85% at T30; none of the patients reporting worsening at T30. Adverse events were mild and related to lumbar puncture.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In our study, nusinersen led to continuous functional improvement over 30-month follow-up and was well tolerated by adults and older children with a wide spectrum of SMA severity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02769-4","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T09:01:39Z","timestamp":1691139699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience"],"prefix":"10.1186","volume":"18","author":[{"given":"Anna","family":"\u0141usakowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"W\u00f3jcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fr\u0105czek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Aragon-Gawi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Potulska-Chromik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Baranowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryszard","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Rosiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Milczarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Konecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Gierlak-W\u00f3jcicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Burlewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-1914","authenticated-orcid":false,"given":"Anna","family":"Kostera-Pruszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"2769_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/344540a0","volume":"344","author":"LM Brzustowicz","year":"1990","unstructured":"Brzustowicz LM, Lehner T, Castilla LH, Penchaszadeh GK, Wilhelmsen KC, Daniels R, et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature. 1990;344:540\u20134.","journal-title":"Nature"},{"key":"2769_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0140-6736(90)91803-I","volume":"336","author":"J Melki","year":"1990","unstructured":"Melki J, Sheth P, Abdelhak S, Burlet P, Bachelot MF, Lathrop MG, et al. Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. The french spinal muscular atrophy investigators. Lancet. 1990;336:271\u20133.","journal-title":"Lancet"},{"key":"2769_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155\u201365.","journal-title":"Cell"},{"key":"2769_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ng0797-265","volume":"16","author":"S Lefebvre","year":"1997","unstructured":"Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997;16:265\u20139.","journal-title":"Nat Genet"},{"key":"2769_CR5","first-page":"393","volume":"15","author":"E Tizzano","year":"2000","unstructured":"Tizzano E, Baiget M. Molecular basis of spinal muscular atrophy: the SMN gene. Neurologia. 2000;15:393\u2013400.","journal-title":"Neurologia"},{"key":"2769_CR6","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999;96:6307\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2769_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, March F, Vencesl\u00e1 A, Rodr\u00edguez-\u00c1lvarez FJ, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28:208\u201315.","journal-title":"Neuromuscul Disord"},{"key":"2769_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20","author":"E Sugarman","year":"2012","unstructured":"Sugarman E, Nagan N, Zhu H, Akmaev V, Zhou Z, Rohlfs E, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of > 72,400 specimens. Eur J Hum Genet. 2012;20:27\u201332.","journal-title":"Eur J Hum Genet"},{"key":"2769_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24864","volume":"81","author":"MA Farrar","year":"2017","unstructured":"Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81:355\u201368.","journal-title":"Ann Neurol"},{"key":"2769_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman RI, Wijngaarde CA, Stam M, Bartels B, Otto LAM, Lemmink HH, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4. Eur J Neurol. 2018;25:512\u20138.","journal-title":"Eur J Neurol"},{"key":"2769_CR11","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","volume":"79","author":"P Kaufmann","year":"2012","unstructured":"Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, Kang PB, et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012;79:1889\u201397.","journal-title":"Neurology"},{"key":"2769_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Finkel R, Montes J, Mazzone ES, Sormani MP, Main M, et al. Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials. Neuromuscul Disord. 2016;26:126\u201331.","journal-title":"Neuromuscul Disord"},{"key":"2769_CR13","doi-asserted-by":"publisher","first-page":"e0199657","DOI":"10.1371\/journal.pone.0199657","volume":"13","author":"J Montes","year":"2018","unstructured":"Montes J, McDermott MP, Mirek E, Mazzone ES, Main M, Glanzman AM, et al. Ambulatory function in spinal muscular atrophy: age-related patterns of progression. PLoS ONE. 2018;13:e0199657.","journal-title":"PLoS ONE"},{"key":"2769_CR14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/ana.25900","volume":"88","author":"G Coratti","year":"2020","unstructured":"Coratti G, Messina S, Lucibello S, Pera MC, Montes J, Pasternak A, et al. Clinical variability in spinal muscular atrophy type III. Ann Neurol. 2020;88:1109\u201317.","journal-title":"Ann Neurol"},{"key":"2769_CR15","doi-asserted-by":"publisher","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","volume":"95","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Stam M, Otto LAM, Bartels B, Asselman FL, van Eijk RPA, et al. Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology. 2020;95:e1988\u201398.","journal-title":"Neurology"},{"key":"2769_CR16","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","volume":"26","author":"NK Singh","year":"2006","unstructured":"Singh NK, Singh NN, Androphy EJ, Singh RN. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol. 2006;26:1333\u201346.","journal-title":"Mol Cell Biol"},{"key":"2769_CR17","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek LM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. 2011;3:72ra18.","journal-title":"Sci Transl Med"},{"key":"2769_CR18","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332.","journal-title":"N Engl J Med"},{"key":"2769_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","volume":"16","author":"G Corrati","year":"2021","unstructured":"Corrati G, Cutrona C, Pera MC, Bovis F, Ponzano M, Chieppa F, et al. 2021 motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analys. Orphanet J Rare Dis. 2021;16:430.","journal-title":"Orphanet J Rare Dis"},{"key":"2769_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625\u201335.","journal-title":"N Engl J Med"},{"key":"2769_CR21","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, et al. Nusinersen safety and efects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry. 2020;91:1166\u201374.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2769_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, Gunther R, Schreiber-Katz O, Osmanovic A, Petri S, et al. Nusinersen in adults with 5q spinal muscular atrophy: a noninterventional, multicentre, observational cohort study. Lancet Neurol. 2020;19:317\u201325.","journal-title":"Lancet Neurol"},{"key":"2769_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/mus.26769","volume":"61","author":"A Veerapandiyan","year":"2020","unstructured":"Veerapandiyan A, Eichinger K, Guntrum D, Kwon J, Baker L, Collins E, et al. Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience. Muscle Nerve. 2020;61:222\u20136.","journal-title":"Muscle Nerve"},{"key":"2769_CR24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/acn3.51514","volume":"9","author":"M Pane","year":"2022","unstructured":"Pane M, Coratti G, Pera MC, Sansone AV, Messina S, d\u2019Amico A, et al. Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy. Ann Clin Transl Neurol. 2022;9:404\u20139. https:\/\/doi.org\/10.1002\/acn3.51514.","journal-title":"Ann Clin Transl Neurol"},{"key":"2769_CR25","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/ene.15501","volume":"29","author":"F V\u00e1zquez-Costa","year":"2022","unstructured":"V\u00e1zquez-Costa F, Povedano M, Nascimiento-Osorio AE, Moreno Escribano A, Kapetanovic Garcia S, Dominguez R, et al. Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts\u2019 study. Eur J Neurol. 2022;29:3337\u201346.","journal-title":"Eur J Neurol"},{"key":"2769_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00234-021-02643-9","volume":"63","author":"G Rosiak","year":"2021","unstructured":"Rosiak G, Lusakowska A, Milczarek K, Konecki D, Fraczek A. Ultra-low radiation dose protocol for CT-guided intrathecal nusinersen injections for patients with spinal muscular atrophy and severe scoliosis. Neuroradiology. 2021;63:539\u201345.","journal-title":"Neuroradiology"},{"key":"2769_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O\u2019Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, Quigley J, Riley S, Sanborn E, Irvine C, Martens WB, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord. 2007;17:693\u20137.","journal-title":"Neuromuscul Disord"},{"key":"2769_CR28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55:869\u201374.","journal-title":"Muscle Nerve"},{"key":"2769_CR29","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mus.25120","volume":"54","author":"S Dunaway Young","year":"2016","unstructured":"Dunaway Young S, Montes J, Kramer SS, Marra J, Salazar R, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016;54:836\u201342.","journal-title":"Muscle Nerve"},{"key":"2769_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","volume":"17","author":"MC Pera","year":"2017","unstructured":"Pera MC, Coratti G, Forcina N, Mazzone ES, Scoto M, Montes J, et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol. 2017;17:39.","journal-title":"BMC Neurol"},{"issue":"3\u2013a Suppl","key":"2769_CR31","first-page":"S55","volume":"25","author":"D Stull","year":"2019","unstructured":"Stull D, Williams V, Houghton K, Williams N, Teynor M. Minimal clinically important differences in motor function in patients with infantile-onset spinal muscular atrophy: results from the phase 3 ENDEAR trial. J Manag Care Spec Pharm. 2019;25(3\u2013a Suppl):S55. March 25, 2019. San Diego, CA.","journal-title":"J Manag Care Spec Pharm"},{"key":"2769_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mus.26419","volume":"59","author":"MC Pera","year":"2019","unstructured":"Pera MC, Coratti G, Mazzone ES, Montes J, Scoto M, et al. Revised upper limb module for spinal muscular atrophy: 12-month changes. Muscle Nerve. 2019;59:426\u201330.","journal-title":"Muscle Nerve"},{"key":"2769_CR33","first-page":"218","volume-title":"Clinical global impressions, ECDEU Assessment Manual for Psychopharmacology, revised","author":"W Guy","year":"1976","unstructured":"Guy W. Clinical global impressions, ECDEU Assessment Manual for Psychopharmacology, revised. Volume ADM 76\u2013338. Rockville: National Institute of Mental Health; 1976. pp. 218\u201322. DHEW Publ. No."},{"key":"2769_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13023-021-01771-y","volume":"16","author":"A Lusakowska","year":"2021","unstructured":"Lusakowska A, Jedrzejowska M, Kaminska A, Janiszewska K, Grochowski P, Zimowski J, et al. Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy. Orphanet J Rare Dis. 2021;16:150.","journal-title":"Orphanet J Rare Dis"},{"key":"2769_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S, Stauber J, Hiebeler M, Greckl E, et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3 \u2013 a prospective observational study. J Neuromuscul Dis. 2019;6:453\u201365.","journal-title":"J Neuromuscul Dis"},{"key":"2769_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3233\/JND-190453","volume":"7","author":"CJJ Yeo","year":"2020","unstructured":"Yeo CJJ, Simeone SD, Townsend EL, Zhang RZ, Swoboda KJ. Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy. J Neuromuscul Dis. 2020;7:257\u201368.","journal-title":"J Neuromuscul Dis"},{"key":"2769_CR37","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1111\/ene.14902","volume":"28","author":"T Meyer","year":"2021","unstructured":"Meyer T, Maier A, Uzelac Z, Hagenacker T, G\u00fcnther R, Schreiber-Katz O, et al. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. Eur J Neurol. 2021;28:2582\u201395.","journal-title":"Eur J Neurol"},{"key":"2769_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","volume":"14","author":"A Pechmann","year":"2019","unstructured":"Pechmann A, K\u00f6nig K, Bernert G, Schachtrup K, Schara U, Schorling D. SMArtCARE- A platform to collect real-life outcome data of patients with spinal muscular atrophy. Orphanet J Rare Dis. 2019;14:18.","journal-title":"Orphanet J Rare Dis"},{"key":"2769_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy-new phenotypes, new challenges, new care implication for care. J Neuromuscul Dis. 2020;7:1\u201313.","journal-title":"J Neuromuscul Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02769-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02769-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02769-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T19:38:59Z","timestamp":1700509139000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02769-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2769"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02769-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"30 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"<b>Ethics approval and consent to participate<\/b>.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients or their caregivers, as appropriate, gave their informed consent for nusinersen treatment (National Health System form for reimbursed treatment program) and for data collection (Ethic Committee approval- BK\/180\/2008).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<b>Consent for publication<\/b>.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AL and AK-P received honoraria for advisory boards and speaking at educational events for Biogen, Novartis\/AveXis, PTC and Roche; AL is a subinvestigator for SUNFISH and JEWELFISH studies; AK-P is a Principal Investigator for SUNFISH and JEWELFISH studies; AK-P and AL are involved in project supported with Institutional grant to Medical University of Warsaw from Biogen POL-SMG-17-11166 (5BIOGEN01); AW, AF, KA-G, ZG-W and RN received honoraria for speaking at educational events for Biogen and Roche; AP-Ch received honoraria for speaking at educational events for Biogen and PTC and is a subinvestigator in the DMD study; MB, PB, GR, DK, KM declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Department of Neurology at the Medical University of Warsaw, Poland, is a member of the European Reference Network for Rare Neuromuscular Diseases (EURO-NMD).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}}],"article-number":"230"}}